Daniel Gilbert,

100%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

No current examples available.

Conflicts of Interest

No current examples available.

Contradictions

No current examples available.

Deceptions

No current examples available.

Recent Articles

Medtronic's Game-Changing Inceptiv: The World's First Closed-Loop Spinal Cord Stimulator for Personalized Chronic Pain Relief

Medtronic's Game-Changing Inceptiv: The World's First Closed-Loop Spinal Cord Stimulator for Personalized Chronic Pain Relief

Broke On: Friday, 26 April 2024 Medtronic's new Inceptiv closed-loop spinal cord stimulator, the world's smallest and thinnest fully implantable system, offers personalized chronic pain relief through real-time adjustments based on biological signals. The device features a rechargeable lithium battery and MRI access with no restrictions.
FDA Delays Approval of Experimental Alzheimer's Drug Donanemab, Sparking Concerns Over Safety and Efficacy

FDA Delays Approval of Experimental Alzheimer's Drug Donanemab, Sparking Concerns Over Safety and Efficacy

Broke On: Saturday, 09 March 2024 The FDA has delayed regulatory action on donanemab, an experimental Alzheimer's drug designed to attack a sticky substance in the brain known as amyloid beta. Clinical trials have shown that it slows cognitive decline of people in the early stages of the disease. The FDA plans to hold a hearing with external advisers to explore its safety and effectiveness before making any decision on approval.